Bioventus Introduces New Products at AAOS
Bioventus Introduces New Products for Spine Surgery, Osteoarthritis at AAOS
ORLANDO – March 2, 2016 – Bioventus, a leader in orthobiologic solutions, today announced it will introduce several new products in booth #1851 at the Annual Meeting of the American Academy of Orthopaedic Surgeons (AAOS) March 1-5 in the Orange County Convention Center. These include GELSYN-3™, a three-injection, hyaluronic acid (HA) based product for pain relief associated with osteoarthritis (OA) of the knee. HA is a naturally occurring molecule that provides for lubrication and cushioning in a normal joint.
This week Bioventus will also introduce CellXtract™ a novel cell and bone marrow extraction tool; and SIGNAFUSE™ Bioactive Bonegraft Putty, which is comprised of a bi-phasic mineral composite combined with a patented bioactive glass and resorbable polymer carrier providing surgeons with exceptional handling properties.
“Bioventus is very pleased to introduce a full portfolio of bone grafting solutions backed by clinical and technical data to benefit patients, surgeons, and hospitals this week at AAOS,” said Tony Bihl, CEO, Bioventus. “We are also excited to speak with attendees about GELSYN-3, our newest HA as well as the rest of our active healing therapies product portfolio. It’s our goal to provide customers with leading orthobiologic products that heal patients quickly and safely while helping them resume and enjoy active lives.”
Also on display in the Bioventus booth will be EXOGEN® Ultrasound Bone Healing System - indicated for the treatment of established non-unions and indicated fresh fractures; SUPARTZ FX® - a five-injection HA for treatment of pain in the knee due to OA; DUROLANE® - a single-injection stabilized HA based upon a natural, safe and proven technology called NASHA®, and indicated for the treatment of mild to moderate OA pain in a variety of joints; OsteoAMP® Allogeneic Morphogenetic Proteins - a uniquely processed allograft bone graft substitute and a suite of additional synthetic and allograft bone graft solutions added with the recent BioStructures acquisition.
About Bioventus
Bioventus LLC is an orthobiologics company that delivers clinically proven, cost-effective products that help people heal quickly and safely. Its mission is to make a difference by helping patients resume and enjoy active lives. Bioventus has two product portfolios for orthobiologics, Bioventus Active Healing Therapies and Bioventus Surgical that make it a global leader in active orthopaedic healing. Built on a commitment to high quality standards, evidence-based medicine and strong ethical behavior, Bioventus is a trusted partner for physicians worldwide.
For more information, visit www.BioventusGlobal.com and follow the company on Twitter @Bioventusglobal
Bioventus, the Bioventus logo, EXOGEN and OsteoAMP are registered trademarks and GELSYN-3, CellXtract and SIGNAFUSE are trademarks of Bioventus LLC. SUPARTZ FX is a registered trademark of Seikagaku Corp. DUROLANE and NASHA are registered trademarks of Galderma S.A.
Summary of Indications for Use
The EXOGEN Ultrasound Bone Healing System is indicated for the non-invasive treatment of established non-unions excluding skull and vertebra. In addition, EXOGEN is indicated for accelerating the time to a healed fracture for fresh, closed, posteriorly displaced distal radius fractures and fresh, closed or Grade I open tibial diaphysis fractures in skeletally mature individuals when these fractures are orthopaedically managed by closed reduction and cast immobilization. There are no known contraindications for the EXOGEN device. Safety and effectiveness have not been established for individuals lacking skeletal maturity, pregnant or nursing women, patients with cardiac pacemakers, on fractures due to bone cancer, or on patients with poor blood circulation or clotting problems. Some patients may be sensitive to the ultrasound gel. Full prescribing information can be found in product labeling at
www.exogen.com or by calling customer service at 1-800-836-4080. A non-union is considered to be established when the fracture site shows no visibly progressive signs of healing.
SUPARTZ FX is indicated for treatment of pain in osteoarthritis (OA) of the knee in patients who have failed to respond adequately to conservative non-pharmacologic therapy and simple analgesics, e.g., acetaminophen.
You should not use SUPARTZ FX if you have infections or skin diseases at the injection site or allergies to avian (bird) products (feathers and eggs). SUPARTZ FX is not approved for pregnant or nursing women, or children. Risks can include general knee pain, warmth and redness or pain at the injection site. Full prescribing information can be found at www.SupartzFX.com or by contacting customer service at 800-836-4080.
DUROLANE (3ml)-Europe: Symptomatic treatment of mild to moderate knee or hip osteoarthritis. In addition, DUROLANE has been approved for the symptomatic treatment associated with mild to moderate osteoarthritis pain in the ankle, shoulder, elbow, wrist, fingers and toes. DUROLANE SJ (1ml)-Europe: Symptomatic treatment associated with mild to moderate osteoarthritis pain in the ankle, elbow, wrist, fingers and toes. Both DUROLANE and DUROLANE SJ are also indicated for pain following joint arthroscopy in the presence of osteoarthritis within 3 months of the procedure. There are no known contraindications. You should not use DUROLANE if you have infections or skin disease at the injection site. DUROLANE has not been tested in pregnant or lactating women, or children. Risks can include transient pain, swelling and/or stiffness at the injection site. Clinical effectiveness has been demonstrated out to 6 months but results may vary depending on various patient factors. DUROLANE is not approved for sale in the United States. Indications presented are those approved in the European Union; indications and product offerings vary by country. Consult with your local Bioventus representative for approved use within your region of interest.
OsteoAMP may be used in situations where an autograft is appropriate, such as spinal fusion procedures. It should be restricted to homologous use for the repair, replacement or reconstruction of musculoskeletal defects. Please see OsteoAMP instructions for use for complete list of contraindications, warnings, and precautions. Full prescribing information can be found in product labeling by contacting customer service at 1-800-836-4080. It is available in the US only.
SIGNAFUSE is a bone void filler device intended for use in bony voids or gaps that are not intrinsic to the stability of bony structure. These defects may be surgically created osseous defects or osseous defects created from traumatic injury to the bone. SIGNAFUSE is indicated to be packed gently into bony voids or gaps of the skeletal system (i.e., extremities, pelvis and posterolateral spine fusion procedures). SIGNAFUSE can also be used with autograft as a bone graft extender in the posterolateral spine. The device provides a bone void filler that is resorbed and replaced with host bone during the healing process. Full prescribing information can be found in product labeling by contacting customer service at 1-949-553-1717. It is available in the US only.
CellXtract is intended for use for aspiration of bone marrow or autologous blood using a standard piston syringe. Full prescribing information can be found in product labeling by contacting customer service at 1-800-836-4080.
GELSYN-3 is indicated for the treatment of pain in osteoarthritis (OA) of the knee in patients who have failed to respond adequately to conservative non-pharmacologic therapy and simple analgesics (e.g., acetaminophen). GELSYN-3 is not to be administered to patients with known hypersensitivity (allergy) to sodium hyaluronate preparations and should not be injected into the knees of patients having knee joint infections or skin diseases or infections in the area of the injection site.
Bioventus Enters Into Agreement with IBSA for Rights to GELSYN-3
Bioventus Enters Into Agreement with IBSA for Rights to GELSYN-3™
DURHAM, NC – February 23, 2016 – Bioventus, a global leader in orthobiologic solutions, today announced it has entered into a multi-year agreement with IBSA (Institut Biochimique SA), a pharmaceutical company based in Switzerland, to secure the exclusive US distribution rights for GELSYN-3™, a three-injection, hyaluronic acid (HA) product for pain relief associated with osteoarthritis (OA) of the knee. Financial terms of the transaction were not disclosed.
“The addition of GELSYN-3 aligns with our strategy to offer a three-injection HA product to the US market,” said Tony Bihl, CEO of Bioventus. “GELSYN-3 gives patients, physicians and payers an effective and safe option for OA pain management.1 HA products can help patients live a more active lifestyle and have been shown recently to potentially delay the time to total knee replacement.”2
Hyaluronic acid products, also known as viscosupplements, are used to lubricate and cushion joints and relieve arthritis pain. GELSYN-3 is indicated for relief of knee pain for up to 26 weeks and received premarket approval from FDA in 2014. Bioventus plans to enter the three-injection HA market and launch GELSYN-3 in Q3 2016.
About IBSA
IBSA Institut Biochimique SA was founded in 1945 by a group of Swiss biologists with its head office in Lugano. IBSA Institut Biochimique represents the headquarters of the IBSA group. After an initial phase of consolidation at national level, IBSA experienced a period of rapid expansion and even developed an international reputation starting in 1985, the year in which the current chairman took over as head of the company.
Under the new management the company adopted a strategy of optimizing the use of active ingredients for developing innovative pharmaceutical forms capable of improving patient compliance and the treatment required. The activities cover 7 main treatment areas (pain/inflammation, rheumatology, reproduction and fertility, endocrinology, urology, dermatology and dermocosmetics, respiratory), with over 60 exclusive patents. Currently the IBSA group employs over 1,800 people and is present in over 80 countries through partnerships and local subsidiaries in Italy, France, Hungary, Slovak Republic, Poland, Turkey, China and Scandinavia.
The production facilities are in Switzerland, Italy and the Far East and all are in strict compliance with the highest standards of quality and in line with current regulations. By controlling the steps from production to the delivery of the finished product, IBSA is capable of guaranteeing high quality standards for all products from the various therapeutic areas.
For more information, visit www.ibsa-international.com
About Bioventus
Bioventus LLC is an orthobiologics company that delivers clinically proven, cost-effective products that help people heal quickly and safely. Its mission is to make a difference by helping patients resume and enjoy active lives. Bioventus has two product portfolios for orthobiologics, Bioventus Active Healing Therapies and Bioventus Surgical that make it a global leader in active orthopaedic healing. Built on a commitment to high quality standards, evidence-based medicine and strong ethical behavior, Bioventus is a trusted partner for physicians worldwide.
For more information, visit www.BioventusGlobal.com and follow the company on Twitter @Bioventusglobal
Media Contact:
Thomas Hill
[email protected]
- Pavelka K and Uebelhart D. Efficacy evaluation of highly purified intra-articular hyaluronic acid (Sinovial®) vs hylan G-F20 (Synvisc®) in the treatment of symptomatic knee osteoarthritis. A double-blind, controlled, randomized, parallel-group non-inferiority study. Osteoarthritis Cartilage 19 (2011):1294-1300.
- Altman R, Lim S, Steen RG, Dasa V. Hyaluronic acid injections are associated with delay of total knee replacement surgery in patients with knee osteoarthritis: evidence from a large U.S. health claims database. PLoS One. 2015;10(12):e0145776.
GELSYN-3 is indicated for the treatment of pain in osteoarthritis (OA) of the knee in patients who have failed to respond adequately to conservative non-pharmacologic therapy and simple analgesics (e.g., acetaminophen). GELSYN-3 is not to be administered to patients with known hypersensitivity (allergy) to sodium hyaluronate preparations and should not be injected into the knees of patients having knee joint infections or skin diseases or infections in the area of the injection site.
Bioventus, the Bioventus logo and GELSYN-3 are registered trademarks of Bioventus. Sinovial is a registered trademark of IBSA. Synvisc is a registered trademark of Genzyme Corporation.
Bioventus Introduces New Products for Spine Surgery, Osteoarthritis at AAOS
Bioventus Introduces New Products for Spine Surgery, Osteoarthritis at AAOS
ORLANDO – March 2, 2016 – Bioventus, a leader in orthobiologic solutions, today announced it will introduce several new products in booth #1851 at the Annual Meeting of the American Academy of Orthopaedic Surgeons (AAOS) March 1-5 in the Orange County Convention Center. These include GELSYN-3™, a three-injection, hyaluronic acid (HA) based product for pain relief associated with osteoarthritis (OA) of the knee. HA is a naturally occurring molecule that provides for lubrication and cushioning in a normal joint.
This week Bioventus will also introduce CellXtract™ a novel cell and bone marrow extraction tool; and SIGNAFUSE™ Bioactive Bonegraft Putty, which is comprised of a bi-phasic mineral composite combined with a patented bioactive glass and resorbable polymer carrier providing surgeons with exceptional handling properties.
“Bioventus is very pleased to introduce a full portfolio of bone grafting solutions backed by clinical and technical data to benefit patients, surgeons, and hospitals this week at AAOS,” said Tony Bihl, CEO, Bioventus. “We are also excited to speak with attendees about GELSYN-3, our newest HA as well as the rest of our active healing therapies product portfolio. It’s our goal to provide customers with leading orthobiologic products that heal patients quickly and safely while helping them resume and enjoy active lives.”
Also on display in the Bioventus booth will be EXOGEN® Ultrasound Bone Healing System - indicated for the treatment of established non-unions and indicated fresh fractures; SUPARTZ FX® - a five-injection HA for treatment of pain in the knee due to OA; DUROLANE® - a single-injection stabilized HA based upon a natural, safe and proven technology called NASHA®, and indicated for the treatment of mild to moderate OA pain in a variety of joints; OsteoAMP® Allogeneic Morphogenetic Proteins - a uniquely processed allograft bone graft substitute and a suite of additional synthetic and allograft bone graft solutions added with the recent BioStructures acquisition.
About Bioventus
Bioventus LLC is an orthobiologics company that delivers clinically proven, cost-effective products that help people heal quickly and safely. Its mission is to make a difference by helping patients resume and enjoy active lives. Bioventus has two product portfolios for orthobiologics, Bioventus Active Healing Therapies and Bioventus Surgical that make it a global leader in active orthopaedic healing. Built on a commitment to high quality standards, evidence-based medicine and strong ethical behavior, Bioventus is a trusted partner for physicians worldwide.
For more information, visit www.BioventusGlobal.com and follow the company on Twitter @Bioventusglobal
Bioventus, the Bioventus logo, EXOGEN and OsteoAMP are registered trademarks and GELSYN-3, CellXtract and SIGNAFUSE are trademarks of Bioventus LLC. SUPARTZ FX is a registered trademark of Seikagaku Corp. DUROLANE and NASHA are registered trademarks of Galderma S.A.
Summary of Indications for Use
The EXOGEN Ultrasound Bone Healing System is indicated for the non-invasive treatment of established non-unions excluding skull and vertebra. In addition, EXOGEN is indicated for accelerating the time to a healed fracture for fresh, closed, posteriorly displaced distal radius fractures and fresh, closed or Grade I open tibial diaphysis fractures in skeletally mature individuals when these fractures are orthopaedically managed by closed reduction and cast immobilization. There are no known contraindications for the EXOGEN device. Safety and effectiveness have not been established for individuals lacking skeletal maturity, pregnant or nursing women, patients with cardiac pacemakers, on fractures due to bone cancer, or on patients with poor blood circulation or clotting problems. Some patients may be sensitive to the ultrasound gel. Full prescribing information can be found in product labeling at www.exogen.com or by calling customer service at 1-800-836-4080. A non-union is considered to be established when the fracture site shows no visibly progressive signs of healing.
SUPARTZ FX is indicated for treatment of pain in osteoarthritis (OA) of the knee in patients who have failed to respond adequately to conservative non-pharmacologic therapy and simple analgesics, e.g., acetaminophen.
You should not use SUPARTZ FX if you have infections or skin diseases at the injection site or allergies to avian (bird) products (feathers and eggs). SUPARTZ FX is not approved for pregnant or nursing women, or children. Risks can include general knee pain, warmth and redness or pain at the injection site. Full prescribing information can be found at www.SupartzFX.com or by contacting customer service at 800-836-4080.
DUROLANE (3ml)-Europe: Symptomatic treatment of mild to moderate knee or hip osteoarthritis. In addition, DUROLANE has been approved for the symptomatic treatment associated with mild to moderate osteoarthritis pain in the ankle, shoulder, elbow, wrist, fingers and toes. DUROLANE SJ (1ml)-Europe: Symptomatic treatment associated with mild to moderate osteoarthritis pain in the ankle, elbow, wrist, fingers and toes. Both DUROLANE and DUROLANE SJ are also indicated for pain following joint arthroscopy in the presence of osteoarthritis within 3 months of the procedure. There are no known contraindications. You should not use DUROLANE if you have infections or skin disease at the injection site. DUROLANE has not been tested in pregnant or lactating women, or children. Risks can include transient pain, swelling and/or stiffness at the injection site. Clinical effectiveness has been demonstrated out to 6 months but results may vary depending on various patient factors. DUROLANE is not approved for sale in the United States. Indications presented are those approved in the European Union; indications and product offerings vary by country. Consult with your local Bioventus representative for approved use within your region of interest.
OsteoAMP may be used in situations where an autograft is appropriate, such as spinal fusion procedures. It should be restricted to homologous use for the repair, replacement or reconstruction of musculoskeletal defects. Please see OsteoAMP instructions for use for complete list of contraindications, warnings, and precautions. Full prescribing information can be found in product labeling by contacting customer service at 1-800-836-4080. It is available in the US only.
SIGNAFUSE is a bone void filler device intended for use in bony voids or gaps that are not intrinsic to the stability of bony structure. These defects may be surgically created osseous defects or osseous defects created from traumatic injury to the bone. SIGNAFUSE is indicated to be packed gently into bony voids or gaps of the skeletal system (i.e., extremities, pelvis and posterolateral spine fusion procedures). SIGNAFUSE can also be used with autograft as a bone graft extender in the posterolateral spine. The device provides a bone void filler that is resorbed and replaced with host bone during the healing process. Full prescribing information can be found in product labeling by contacting customer service at 1-949-553-1717. It is available in the US only.
CellXtract is intended for use for aspiration of bone marrow or autologous blood using a standard piston syringe. Full prescribing information can be found in product labeling by contacting customer service at 1-800-836-4080.
GELSYN-3 is indicated for the treatment of pain in osteoarthritis (OA) of the knee in patients who have failed to respond adequately to conservative non-pharmacologic therapy and simple analgesics (e.g., acetaminophen). GELSYN-3 is not to be administered to patients with known hypersensitivity (allergy) to sodium hyaluronate preparations and should not be injected into the knees of patients having knee joint infections or skin diseases or infections in the area of the injection site.